(Q24797853)

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1064141

Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1064141

The sonic hedgehog-patched-gli pathway in human development and disease

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1064141

Transcriptional profiling of the Sonic hedgehog response: a critical role for N-myc in proliferation of neuronal precursors

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1064141

Update on the management of inflammatory breast cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1064141

Ten-year outcome after combined modality therapy for inflammatory breast cancer.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1064141

Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1064141

Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1064141

Prediction of outcome in locally advanced breast cancer by post-chemotherapy nodal status and baseline serum tumour markers

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1064141

WISP3 is a novel tumor suppressor gene of inflammatory breast cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1064141

Cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in inflammatory breast carcinoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1064141

AP-1 in mouse development and tumorigenesis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1064141

Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1064141

RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1064141

Molecular cytogenetic analysis of 11 new breast cancer cell lines

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1064141

A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1064141

Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1064141

Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1064141

p53 mutations and overexpression in locally advanced breast cancers

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1064141

Prognostic factors in inflammatory breast cancer and therapeutic implications

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1064141

Oestrogen and progesterone cytosolic receptors in clinically inflammatory tumours of the human breast

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1064141

Pathological assessment of response to induction chemotherapy in breast cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1064141

Inflammatory breast cancer: a review

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1064141

Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1064141

Locally advanced breast cancer with inflammatory component: a clinical entity with a poor prognosis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1064141

A novel human xenograft model of inflammatory breast cancer.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1064141

Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1064141

Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1064141

Poor prognosis of p53 gene mutation and nuclear overexpression of p53 protein in inflammatory breast carcinoma

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1064141

Breast cancers in the evolutive phase

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1064141

Multivariate analysis of survival in inflammatory breast cancer: impact of intensity of chemotherapy in multimodality treatment

30 May 2018

1 reference

Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy

21 January 2018

1 reference

Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'.

21 January 2018

1 reference

Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome?

21 January 2018

1 reference

Persistent E-cadherin expression in inflammatory breast cancer

21 January 2018

1 reference

Case control study of prognostic markers and disease outcome in inflammatory carcinoma breast: a unique clinical experience

21 January 2018

1 reference

Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancer

21 January 2018

1 reference

Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature.

21 January 2018

1 reference

Two prognostic groups of inflammatory breast cancer have distinct genotypes.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1064141

An intact overexpressed E-cadherin/alpha,beta-catenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1064141

Survival after autologous hematopoietic stem cell transplantation for patients with inflammatory breast carcinoma

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1064141

Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1064141

Management of locally advanced carcinoma of the breast. II. Inflammatory carcinoma.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1064141

Inflammatory breast carcinoma: pathological or clinical entity?

28 November 2018

1 reference

12 December 2020

Tumor-infiltrating endothelial cells and endothelial precursor cells in inflammatory breast cancer

1 reference

12 December 2020

Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer

1 reference

12 December 2020

Evidence of chromosome regions and gene involvement in inflammatory breast cancer

1 reference

12 December 2020

Inflammatory Breast Carcinoma and Noninflammatory Locally Advanced Breast Carcinoma: Distinct Clinicopathologic Entities?

1 reference

12 December 2020

Inflammatory breast carcinoma: outcomes with trimodality therapy for nonmetastatic disease

1 reference

12 December 2020

Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) program

1 reference

12 December 2020

Inflammatory breast cancer. Determination of prognostic factors by univariate and multivariate analysis

1 reference

12 December 2020

Secondary inflammatory breast cancer: treatment options

1 reference

12 December 2020

Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance

1 reference

12 December 2020

Inflammatory carcinoma of the breast: treatment results on 107 patients

1 reference

12 December 2020

Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease.

1 reference

12 December 2020

Therapeutic strategies in inflammatory breast carcinoma based on prognostic factors

1 reference

12 December 2020

Inflammatory breast carcinoma: an immunohistochemical study using monoclonal anti-pHER-2/neu, pS2, cathepsin, ER and PR

1 reference

12 December 2020

Association of c-erbB2-gene amplification with poor prognosis in non-inflammatory breast carcinomas but not in carcinomas of the inflammatory type

1 reference

12 December 2020

Inflammatory carcinomas of the breast: A clinical, pathological, or a clinical and pathological definition?

1 reference

12 December 2020

Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience

1 reference

12 December 2020

Pattern of failure in patients with inflammatory breast cancer treated by alternating radiotherapy and chemotherapy

1 reference

12 December 2020

Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients

1 reference

12 December 2020

Inflammatory breast carcinoma: comparison of survival of those diagnosed clinically, pathologically, or with both features

1 reference

12 December 2020

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy

1 reference

12 December 2020

Identifiers

DOI

10.1186/BCR997

1 reference

Dimensions Publication ID

1025618979

0 references

1 reference

1 reference

PubMed publication ID

15743511

1 reference